To detect more low-volume advanced-stage ovarian cancers, Spoik et al. evaluated changes in CA125 cutoff from 35 U/mL to 70 U/mL and 100 U/mL, which resulted in specificities of 99% and 99.9%, respectively. Here, MUC16 is linked to ovarian cancer.